| Year |
Citation |
Score |
| 2023 |
Mestre TA, Kalia LV. α-synuclein seed amplification in Parkinson's disease. The Lancet. Neurology. 22: 984-985. PMID 37863603 DOI: 10.1016/S1474-4422(23)00374-5 |
0.325 |
|
| 2023 |
Nim S, O'Hara DM, Corbi-Verge C, Perez-Riba A, Fujisawa K, Kapadia M, Chau H, Albanese F, Pawar G, De Snoo ML, Ngana SG, Kim J, El-Agnaf OMA, Rennella E, Kay LE, ... ... Kalia LV, et al. Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson's disease. Nature Communications. 14: 2150. PMID 37076542 DOI: 10.1038/s41467-023-37464-2 |
0.348 |
|
| 2021 |
Chen KS, Menezes K, Rodgers JB, O'Hara DM, Tran N, Fujisawa K, Ishikura S, Khodaei S, Chau H, Cranston A, Kapadia M, Pawar G, Ping S, Krizus A, Lacoste A, ... ... Kalia LV, et al. Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans. Molecular Neurodegeneration. 16: 77. PMID 34772429 DOI: 10.1186/s13024-021-00497-6 |
0.41 |
|
| 2021 |
Barbuti PA, Barker RA, Brundin P, Przedborski S, Papa SM, Kalia LV, Mochizuki H. Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 33963552 DOI: 10.1002/mds.28628 |
0.32 |
|
| 2021 |
O'Hara DM, Kapadia M, Ping S, Kalia SK, Kalia LV. Semi-Quantitative Determination of Dopaminergic Neuron Density in the Substantia Nigra of Rodent Models using Automated Image Analysis. Journal of Visualized Experiments : Jove. PMID 33616088 DOI: 10.3791/62062 |
0.326 |
|
| 2020 |
Visanji NP, Madan P, Lacoste AMB, Buleje I, Han Y, Spangler S, Kalia LV, Alford SH, Marras C. Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease. Pharmacoepidemiology and Drug Safety. PMID 33219601 DOI: 10.1002/pds.5176 |
0.31 |
|
| 2020 |
Mylvaganam S, Earnshaw R, Heymann G, Kalia SK, Kalia LV. C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside. Current Neuropharmacology. PMID 33200713 DOI: 10.2174/1570159X18666201116145507 |
0.356 |
|
| 2020 |
Friesen EL, Zhang YT, Earnshaw R, De Snoo ML, O'Hara DM, Agapova V, Chau H, Ngana S, Chen KS, Kalia LV, Kalia SK. BAG5 Promotes Alpha-Synuclein Oligomer Formation and Functionally Interacts With the Autophagy Adaptor Protein p62. Frontiers in Cell and Developmental Biology. 8: 716. PMID 32850835 DOI: 10.3389/fcell.2020.00716 |
0.532 |
|
| 2020 |
O'Hara DM, Pawar G, Kalia SK, Kalia LV. LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease? Frontiers in Neuroscience. 14: 577. PMID 32625052 DOI: 10.3389/fnins.2020.00577 |
0.379 |
|
| 2020 |
Maclagan LC, Visanji NP, Cheng Y, Tadrous M, Lacoste AMB, Kalia LV, Bronskill SE, Marras C. Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. Pharmacoepidemiology and Drug Safety. PMID 32410265 DOI: 10.1002/Pds.5015 |
0.305 |
|
| 2020 |
O'Hara DM, Kalia SK, Kalia LV. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease. Critical Reviews in Clinical Laboratory Sciences. 1-17. PMID 32116096 DOI: 10.1080/10408363.2019.1711359 |
0.406 |
|
| 2020 |
Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, et al. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. PMID 32102975 DOI: 10.1212/Wnl.0000000000009107 |
0.353 |
|
| 2020 |
McKinnon C, De Snoo ML, Gondard E, Neudorfer C, Chau H, Ngana SG, O'Hara DM, Brotchie JM, Koprich JB, Lozano AM, Kalia LV, Kalia SK. Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein. Acta Neuropathologica Communications. 8: 17. PMID 32059750 DOI: 10.1186/s40478-020-0894-0 |
0.399 |
|
| 2018 |
Kalia LV. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid. Parkinsonism & Related Disorders. PMID 30466800 DOI: 10.1016/j.parkreldis.2018.11.016 |
0.332 |
|
| 2018 |
Hara DMO, Kalia SK, Kalia LV. Emerging Disease-Modifying Strategies Targeting α-Synuclein for the Treatment of Parkinson Disease. British Journal of Pharmacology. PMID 29722028 DOI: 10.1111/bph.14345 |
0.368 |
|
| 2017 |
Friesen EL, De Snoo ML, Rajendran L, Kalia LV, Kalia SK. Chaperone-Based Therapies for Disease Modification in Parkinson's Disease. Parkinson's Disease. 2017: 5015307. PMID 28913005 DOI: 10.1155/2017/5015307 |
0.377 |
|
| 2017 |
Koprich JB, Kalia LV, Brotchie JM. Animal models of α-synucleinopathy for Parkinson disease drug development. Nature Reviews. Neuroscience. PMID 28747776 DOI: 10.1038/nrn.2017.75 |
0.363 |
|
| 2017 |
Rosborough K, Patel N, Kalia LV. α-Synuclein and Parkinsonism: Updates and Future Perspectives. Current Neurology and Neuroscience Reports. 17: 31. PMID 28324300 DOI: 10.1007/s11910-017-0737-y |
0.375 |
|
| 2017 |
Breen DP, Kalia LV. Exploiting the aggregation properties of alpha-synuclein for diagnostic purposes. Movement Disorders : Official Journal of the Movement Disorder Society. 32: 106. PMID 27896833 DOI: 10.1002/mds.26884 |
0.506 |
|
| 2016 |
Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, Lang AE. α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. Trends in Neurosciences. PMID 27776749 DOI: 10.1016/J.Tins.2016.09.003 |
0.409 |
|
| 2016 |
Rowland NC, Kalia SK, Kalia LV, Larson PS, Lim DA, Bankiewicz KS. Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease. Molecular Therapy. Methods & Clinical Development. 3: 15051. PMID 26817024 DOI: 10.1038/Mtm.2015.51 |
0.333 |
|
| 2016 |
Kalia LV, Lang AE. Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD. Nature Reviews. Neurology. 12: 65-6. PMID 26782330 DOI: 10.1038/nrneurol.2015.249 |
0.303 |
|
| 2015 |
Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 1442-50. PMID 26208210 DOI: 10.1002/mds.26354 |
0.322 |
|
| 2015 |
Kalia LV, Kalia SK. α-Synuclein and Lewy pathology in Parkinson's disease. Current Opinion in Neurology. 28: 375-81. PMID 26110807 DOI: 10.1097/WCO.0000000000000215 |
0.396 |
|
| 2015 |
Kalia LV, Lang AE. Parkinson's disease. Lancet. PMID 25904081 DOI: 10.1016/S0140-6736(14)61393-3 |
0.358 |
|
| 2014 |
Beilina A, Rudenko IN, Kaganovich A, Civiero L, Chau H, Kalia SK, Kalia LV, Lobbestael E, Chia R, Ndukwe K, Ding J, Nalls MA, Olszewski M, et al. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America. 111: 2626-31. PMID 24510904 DOI: 10.1073/Pnas.1318306111 |
0.315 |
|
| 2014 |
AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 6-23. PMID 24085420 DOI: 10.1007/s13311-013-0218-1 |
0.329 |
|
| 2013 |
Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE. α-Synuclein oligomers and clinical implications for Parkinson disease. Annals of Neurology. 73: 155-69. PMID 23225525 DOI: 10.1002/Ana.23746 |
0.585 |
|
| 2011 |
Kalia LV, Kalia SK, Chau H, Lozano AM, Hyman BT, McLean PJ. Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). Plos One. 6: e14695. PMID 21358815 DOI: 10.1371/Journal.Pone.0014695 |
0.582 |
|
| Show low-probability matches. |